Jazz Pharma has agreed a $7.2 billion deal to by GW Pharmaceuticals and its pioneering cannabis-derived medicines, headed by childhood epilepsy drug Epidiolex. Nasdaq-listed GW is in line for $220 ...

In 2021, the company acquired GW Pharmaceuticals for $7.2bn, gaining the seizure medication Epidiolex (cannabidiol). In February 2024, it licensed a KRAS inhibitor programme from UK-based Redx ...

After bursting onto the scene several years ago with considerable fanfare, much of the hype about cannabis stocks has quietly died down, and ...

GW Pharmaceuticals ended 2017 by filing its childhood epilepsy drug Epidiolex with regulators in the US and EU, setting up a potential launch for a drug that could transform the company's fortunes.

Focus needs to shift from a push to capital-, tech- and skill-intensive sectors to labour- & low-skill intensive ones.

The NSE Nifty 50 on Tuesday rose 0.04% to 23,668.65 after crossing 23,800 intraday, while the BSE Sensex ended 0.04% higher.

VIDEO: some retail investors have been trying to catch the proverbial ‘falling knife’ with Tesla's stock.

Adolescents with alopecia areata achieve hair regrowth with 80% or more of scalp coverage while taking the Janus kinase inhibitor baricitinib, a phase 3 study finds.

Germany is to revive a stalled programme to bring about new 20 gigawatts (GW) of new gas-fired power ... battery production, pharmaceuticals and hydrogen are to be strengthened.